Ponatinib, which targets PDGFR, VEGFR and FGFR, was initially approved for the treatment of refractory chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) in 2012 (Pao et al., 2004; Cortes et al., 2018), then it entered two clinical trials in 2014 for the treatment of malignant neoplasm with FGFR fusions or activating mutations (NCT02265341, NCT02272998). This evidence concerns the gene KDR and chronic myelogenous leukemia, BCR-ABL1 positive.